Study guide
3.1 CKD-Mineral and Bone Disorder (CKD-MBD)
BONENT Certified Hemodialysis Nurse CHN
Track your progress as you read
Finished sections get a check mark.
1 Exam Orientation
1.1 Current CHN Exam Facts and Study Strategy
2 Chapter 1: Renal Anatomy, Physiology & CKD Pathophysiology
2.1 Nephron Physiology & Endocrine Functions 2.2 Acute Kidney Injury & Chronic Kidney Disease Staging 2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD
3 Chapter 2: CKD-MBD, Uremia & Clinical Manifestations
3.1 CKD-Mineral and Bone Disorder (CKD-MBD) 3.2 Uremic Syndrome & Multi-System Complications 3.3 Dialysis Patient Education & Nutritional Management
4 Individualized Nursing Care
4.1 Nursing Assessment, Planning and Evaluation 4.2 Treatment Records and Safe Handoffs 4.3 Psychosocial Assessment, Counseling and Referral
5 Chapter 3: Principles of Hemodialysis & Dialysate Chemistry
5.1 Transport Mechanisms: Diffusion, Convection & Ultrafiltration 5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux 5.3 Dialysate Composition & Concentrate Formulations 5.4 Hemodialysis Adequacy: Urea Kinetics, Kt/V & URR
6 Chapter 4: Vascular Access: Fistulas, Grafts & Catheters
6.1 Arteriovenous Fistulas & Arteriovenous Grafts 6.2 Physical Examination, Surveillance & Monitoring of Access 6.3 Central Venous Catheters & CDC Infection Prevention
7 Chapter 5: Cannulation Practice & Access Complications
7.1 Cannulation Techniques: Rope-Ladder, Buttonhole & Needle Sizing 7.2 Vascular Access Stenosis, Thrombosis & Steal Syndrome 7.3 Access Infiltration, Pseudoaneurysms & Hemorrhage Management
8 Chapter 6: Hemodialysis Treatment Delivery & Circuit Monitoring
8.1 Pre-Dialysis Assessment, Target Dry Weight & UFR Limits 8.2 Extracorporeal Circuit Setup, Priming & Safety Alarms 8.3 Anticoagulation Management: Heparin Protocols & Citrate 8.4 Treatment Termination, Hemostasis & Post-Dialysis Assessment
9 Equipment and Laboratory Skills
9.1 Ancillary Equipment and Bedside Safety 9.2 Blood Sampling, Laboratory Trends and Critical Results
10 Chapter 7: Acute Intradialytic Complications & Emergencies
10.1 Intradialytic Hypotension & Muscle Cramping 10.2 Dialysis Disequilibrium Syndrome & Neurological Events 10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B) 10.4 Critical Emergencies: Air Embolism, Hemolysis & Blood Loss
11 Extended and Acute Treatment
11.1 Sequential UF, Hemofiltration and Hemoperfusion 11.2 Acute Kidney Injury and High-Risk Dialysis Initiation
12 Chapter 8: Nephrology Pharmacology in Hemodialysis
12.1 Anemia Management: ESAs & Intravenous Iron Therapy 12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics 12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing
13 Home and Peritoneal Dialysis
13.1 Home Dialysis Selection and Adult Learning 13.2 Home Setup, Monitoring and Emergency Readiness 13.3 Peritoneal Dialysis Principles and Nursing Care
14 Kidney Transplantation
14.1 Transplant Benefits, Burdens and Modality Counseling 14.2 Transplant Indications, Contraindications and Referral 14.3 Pretransplant Workup and Waiting-List Coordination 14.4 Immunosuppressants, Interactions and Patient Teaching 14.5 Returning to Dialysis After Graft Failure 14.6 New-Graft Monitoring and Urgent Changes
15 Chapter 9: Water Treatment Systems & Dialyzer Reprocessing
15.1 AAMI/ISO Water Treatment Architecture & Components 15.2 Chemical Contaminant Monitoring & Total Chlorine Testing 15.3 Microbiological Standards, Endotoxin Surveillance & Sampling 15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety
16 Clinical Unit Management
16.1 Evaluating Dialysis Technology and Supplies 16.2 Staffing, Personnel Policies and Standards of Care
17 Chapter 10: Supervision, Administration & Professional Practice
17.1 RN Delegation, Technician Supervision & Nurse Practice Acts 17.2 CMS Conditions for Coverage & Interdisciplinary Care Planning 17.3 Dialysis Unit Infection Control & Environmental Safety 17.4 Quality Improvement (ESRD QIP), Ethics & Palliative Care
18 Professional Development
18.1 Professional Literature, Organizations and Continuing Learning 18.2 Research Design, Implementation and Evidence Interpretation 18.3 Staff Training, Competency and Remediation
19 Environmental Hazards and Emergency Planning
19.1 Chemical Agents, Disinfection and Exposure Control 19.2 Biological Hazards and Occupational Injury Response 19.3 Fire, Threats and Power or Water Interruptions
3.1 CKD-Mineral and Bone Disorder (CKD-MBD)
Key Takeaways Explain This Topic AI
Phosphate retention and reduced calcitriol contribute to secondary hyperparathyroidism.
PTH trends and assay limits inform turnover assessment; a numerical cutoff does not prove bone histology.
KDIGO suggests dialysis PTH approximately two to nine times the assay upper normal limit.
Calciphylaxis requires urgent multidisciplinary assessment, wound care and individualized treatment.
Last updated: October 2026
Chronic Kidney Disease-Mineral and Bone Disorder ( CKD-MBD ) is a systemic disorder that develops as renal function declines. Rather than viewing skeletal lesions in isolation, clinical nephrology defines CKD-MBD as an interrelated triad: biochemical abnormalities of calcium, phosphorus, parathyroid hormone ( PTH ), and fibroblast growth factor 23 ( FGF-23 ); bone remodeling abnormalities (renal osteodystrophy); and extra-skeletal vascular and soft-tissue calcification. In maintenance hemodialysis, CKD-MBD is a leading driver of cardiovascular death and fractures.
Pathophysiologic Cascade of CKD-MBD
The cascade begins as declining glomerular filtration rate ( GFR ) impairs renal phosphorus clearance, producing transient hyperphosphatemia .
Phosphate Retention, FGF-23, and Klotho
In response to early phosphate retention, osteocytes secrete Fibroblast Growth Factor 23 (FGF-23) , a 32 kDa phosphaturic hormone. Binding to the Klotho coreceptor complex in renal proximal tubules, FGF-23 downregulates sodium-phosphate cotransporters to stimulate urinary phosphate excretion. However, high circulating FGF-23 and hyperphosphatemia directly inhibit renal 1-alpha-hydroxylase (CYP27B1). This suppresses the synthesis of active 1,25-dihydroxyvitamin D [calcitriol, 1 , 25 ( OH ) 2 D 1,25(\text{OH})_2\text{D} 1 , 25 ( OH ) 2 D ] from its precursor 25-hydroxyvitamin D.
Calcitriol Deficiency and Parathyroid Hyperplasia
Calcitriol deficiency reduces active gastrointestinal calcium absorption and can contribute to hypocalcemia ; calcium values also depend on diet, binders, dialysate and other therapies. Simultaneously, low calcitriol eliminates normal negative feedback on parathyroid chief cells. Hypocalcemia, hyperphosphatemia, and calcitriol deficiency stimulate the parathyroid glands to hypersecrete PTH, establishing Secondary Hyperparathyroidism (sHPT) .
Over years, initial diffuse polyclonal chief cell hyperplasia progresses to nodular monoclonal hyperplasia . In nodular tissue, cells downregulate calcium-sensing receptors (CaSR) and vitamin D receptors ( VDR ). Unresponsive to calcium or vitamin D suppression, the glands transition to autonomous tertiary hyperparathyroidism , causing refractory hypercalcemia that often requires surgical parathyroidectomy.
The Renal Osteodystrophy Spectrum
Renal osteodystrophy describes the skeletal abnormalities resulting from CKD-MBD, classified primarily by bone turnover.
High-Turnover vs. Low-Turnover Bone Disease
Osteitis Fibrosa Cystica (High-Turnover): Driven by severe sHPT with markedly elevated intact PTH ( iPTH ). High PTH accelerates bone resorption by osteoclasts and chaotic formation of woven collagen by osteoblasts. Histology shows marrow peritrabecular fibrosis , brown tumors (osteoclastomas), cortical thinning, bone pain, elevated bone-specific alkaline phosphatase ( BSAP ), and high fracture risk.
Adynamic Bone Disease (Low-Turnover): Characterized by profound cellular quiescence and reduced bone formation without marrow fibrosis. Most often iatrogenic, resulting from excessive calcium binders or active vitamin D oversuppressing PTH. Diabetes and other patient factors also contribute; the pattern does not establish histology by itself. The inactive skeleton cannot buffer acute mineral loads, driving extra-skeletal vascular calcification.
Osteomalacia (Low-Turnover): Characterized by accumulation of unmineralized osteoid seams. Historically caused by aluminum toxicity from aluminum-based binders or contaminated dialysate; now occasionally seen with severe calcitriol and nutritional vitamin D deficiency.
Bone Disease Comparison
- Feature Osteitis Fibrosa Cystica Adynamic Bone Disease Osteomalacia
- Turnover Rate High bone turnover Low bone turnover Low turnover with defective mineralization
Intact PTH Markedly elevated, interpreted with assay and trend Low or oversuppressed, interpreted with assay and trend Low to normal
Bone Alk Phos Markedly elevated Low to normal Variable to elevated
Histology Peritrabecular marrow fibrosis, woven bone Marked hypocellularity, thin osteoid seams Wide, unmineralized osteoid seams
Primary Risk Brown tumors, skeletal deformity, bone pain Accelerated arterial calcification, fractures Severe osteomalacic bone pain, fractures
Extra-Skeletal and Vascular Calcification
Assess serial calcium and phosphorus individually and together; an elevated product alone neither diagnoses calciphylaxis nor dictates treatment.
Medial Arterial and Valvular Calcification
Unlike intimal atherosclerosis, uremic calcification predominantly affects the tunica media of arteries ( Mönckeberg sclerosis ). Elevated phosphate and uremic toxins induce vascular smooth muscle cells to transdifferentiate into osteoblast-like cells that deposit hydroxyapatite. Medial calcification leads to arterial stiffening, loss of vascular compliance, widened pulse pressure, and severe left ventricular hypertrophy (LVH) . In the heart, metastatic calcification stiffens the mitral and aortic valve rings, causing valvular stenosis, regurgitation, and cardiac conduction blocks.
Calciphylaxis (Calcific Uremic Arteriolopathy)
Calciphylaxis is uncommon but life threatening. Ischemic tissue injury, severe pain and secondary infection demand urgent coordinated care.
Pathogenesis and Risk Factors
Small-vessel calcification, thrombosis and tissue ischemia contribute to the syndrome. Risk assessment includes mineral abnormalities, obesity, diabetes, nutritional status and warfarin exposure, but none independently proves the diagnosis. A normal calcium or phosphorus result does not exclude it.
Clinical Presentation and Lesion Progression
Lesions emerge on adipose-dense tissue (thighs, abdomen, buttocks, breasts). Initial lesions present as excruciatingly painful violaceous plaques or subcutaneous nodules with livedo reticularis patterns. As microvascular thrombosis produces transmural cutaneous infarction, lesions rapidly progress into jagged, ischemic, non-healing ulcers covered with thick black necrotic eschars and surrounding violaceous borders.
Multidisciplinary Management
Calciphylaxis is a clinical emergency because ischemic ulcers cause severe pain and infection risk. Promptly report pain out of proportion to visible findings, violaceous changes, nodules or ulceration. The specialist team determines whether biopsy is useful and safe; biopsy is not a routine nursing procedure. Management includes wound assessment, infection treatment when present, adequate nutrition, pain control and correction of mineral abnormalities. Wound debridement is individualized to necrosis and infection rather than prohibited for every patient.
Review calcium loading, active vitamin D, calcimimetic therapy and warfarin with the prescriber. Nurses must not independently stop all medications or lower dialysate calcium to an unprescribed level. Sodium thiosulfate is sometimes used off label, with limited outcome evidence; monitor ordered therapy for nausea, hypotension, sodium/fluid burden and metabolic acidosis. No dose or number of dialysis sessions guarantees healing.
PTH values suggest turnover patterns but do not establish bone histology. KDIGO suggests approximately two to nine times the assay’s upper normal limit in dialysis, with marked trends prompting review. For an assay upper limit of 65 pg/mL, that approximate range is 130–585 pg/mL; it is not an instruction to force every result to 150–600. Very low PTH raises concern about low turnover; very high PTH raises concern about high turnover. When knowing the bone lesion would change treatment, the specialist may consider bone biopsy.